Removing Barriers Between Patients and Life-Changing Treatments
For patients with rare diseases, access can be the single most critical component of care. Aegerion provides a range of programs and services designed to reduce delays, improve adherence, and help patients and families navigate the healthcare system.
Patient Access & Support Programs
Our access and support services include:
Named-patient and early-access programs for pre-approval treatment
Compassionate use programs where approved therapies are not otherwise available
Insurance and reimbursement support in collaboration with payers and providers
Education and adherence initiatives tailored to complex conditions
We believe access is not just about availability — it’s about support, affordability, and empowerment.
Orphan Drug Commercialization
Helping Breakthrough Therapies Reach Those Who Need Them Most
Aegerion Pharmaceuticals UK specializes in the regulatory, operational, and strategic processes required to commercialize orphan and ultra-orphan therapies in the UK and across the European market. Our deep understanding of the rare disease landscape enables us to navigate the unique challenges of small patient populations, complex clinical data, and strict approval frameworks.
